Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study
Authors
Yan Li (ORCID: https://orcid.org/0000-0003-1146-5578)
Hang Yuan (ORCID: https://orcid.org/0000-0003-2607-4334)
Hong-Tao Hu (ORCID: https://orcid.org/0000-0002-5432-4014)
Ke Zhao (ORCID: https://orcid.org/0000-0002-0224-6894)
Quan-Jun Yao
Yanan Zhao
Lifeng Wang (ORCID: https://orcid.org/0000-0002-1096-7720)
Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study
Yan Li, Hang Yuan, Hong-Tao Hu, Ke Zhao et al.
Citations
1 citations
Journal
Frontiers in Immunology
Topics
Hepatocellular Carcinoma Treatment and Prognosis
Field-Weighted Citation Impact (FWCI)
1.32
article
Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study
Yan Li, Hang Yuan, Hong-Tao Hu, Ke Zhao, Quan-Jun Yao, Yanan Zhao, Lifeng Wang, Ho-Young Song, Xiang Geng